Contraceptive Market Size, Share & Trends Analysis Report By Product (Contraceptive Devices, Contraceptive Drugs), By Region (North America, APAC, EU, Latin America), And Segment Forecasts, 2022 - 2030
Description
Contraceptive Market Size, Share & Trends Analysis Report By Product (Contraceptive Devices, Contraceptive Drugs), By Region (North America, APAC, EU, Latin America), And Segment Forecasts, 2022 - 2030
Contraceptive Market Growth & Trends
The global contraceptive market size is expected to reach USD 45.1 billion by 2030, registering a CAGR of 6.01% from 2022 to 2030, based on a new report by Grand View Research, Inc. The growing prevalence of Sexually Transmitted Infections (STIs), especially HIV, and the introduction of new products exhibiting improved efficacy is expected to drive the industry growth during the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute to market growth. The government spending on contraceptives is growing rapidly.
This is expected to drive the growth of the market over the forecast period. According to the Family Planning 2020 Women at the Center report, Australia provided USD 22.2 million in bilateral family planning funding for the 2017 - 2018 fiscal year. The U.S. provided USD 630.6, the U.K. provided USD 292.2, Canada provided USD 81.8, and Germany provided USD 51.3 in bilateral family planning funding for the 2017 - 2018 fiscal year. The COVID-19 pandemic has negatively impacted the global industry. The negative impact can be attributed to the supply-chain disruption, and decline in demand for sexual and reproductive health services globally.
As per the Impact of COVID-19 on access to contraceptives in the LAC region by UNFPA, in Brazil, around 195,658 public-sector users were unable to access contraceptives with moderate disruption for six months during the pandemic, and around 97,829 public-sector users were unable to access contraceptives with low disruptions for three months, and around 391,316 public-sector users were unable to access contraceptives with high disruptions for twelve months. The industry is highly competitive with the presence of many major players. Companies are majorly investing in R&D and are adopting other strategies including M&As and expanding product pipelines. For instance, in April 2021, FDA approved a combination tablet of estetrol and drospirenone
Contraceptive Market Report Highlights
Contraceptive Market Growth & Trends
The global contraceptive market size is expected to reach USD 45.1 billion by 2030, registering a CAGR of 6.01% from 2022 to 2030, based on a new report by Grand View Research, Inc. The growing prevalence of Sexually Transmitted Infections (STIs), especially HIV, and the introduction of new products exhibiting improved efficacy is expected to drive the industry growth during the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute to market growth. The government spending on contraceptives is growing rapidly.
This is expected to drive the growth of the market over the forecast period. According to the Family Planning 2020 Women at the Center report, Australia provided USD 22.2 million in bilateral family planning funding for the 2017 - 2018 fiscal year. The U.S. provided USD 630.6, the U.K. provided USD 292.2, Canada provided USD 81.8, and Germany provided USD 51.3 in bilateral family planning funding for the 2017 - 2018 fiscal year. The COVID-19 pandemic has negatively impacted the global industry. The negative impact can be attributed to the supply-chain disruption, and decline in demand for sexual and reproductive health services globally.
As per the Impact of COVID-19 on access to contraceptives in the LAC region by UNFPA, in Brazil, around 195,658 public-sector users were unable to access contraceptives with moderate disruption for six months during the pandemic, and around 97,829 public-sector users were unable to access contraceptives with low disruptions for three months, and around 391,316 public-sector users were unable to access contraceptives with high disruptions for twelve months. The industry is highly competitive with the presence of many major players. Companies are majorly investing in R&D and are adopting other strategies including M&As and expanding product pipelines. For instance, in April 2021, FDA approved a combination tablet of estetrol and drospirenone
Contraceptive Market Report Highlights
- The contraceptive device segment held the largest market share in 2021 owing to higher success rates and the single-use nature of the devices
- Based on products, the contraceptive drugs segment is expected to witness the fastest CAGR during the forecast period owing to the affordability, easy accessibility, and significant success rates pertaining to these medications
- North America accounted for the largest revenue share in 2021. The presence of sophisticated healthcare infrastructure, high user awareness levels, and easy product availability are key factors responsible for the region’s high share
- Asia Pacific is expected to witness substantial growth during the forecast period owing to rapidly rising population levels and the consequent rise in demand for contraception
- The presence of government initiatives in countries, such as India, China, Sri Lanka, Pakistan, and Bangladesh, aimed at slowing down population growth and the prevalence of STDs are expected to promote market growth
Table of Contents
100 Pages
- Chapter 1 Herpes Simplex Virus Treatment Market: Methodology and Scope
- 1.1 Research Methodology
- 1.2 Research Assumptions
- 1.2.1 Estimates and forecast timeline
- 1.3 Information Procurement
- 1.3.1 Purchased database
- 1.3.2 GVR’s internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.4 Information or Data Analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity flow analysis
- 1.6.1.1 Approach 1: Commodity flow approach
- 1.6.2 Volume price analysis (model 2)
- 1.6.2.1 Approach 2: Volume price analysis
- 1.6.2.2 Revenue modeling
- 1.7 List of Secondary Sources
- 1.8 List of Primary Sources
- Chapter 2 Herpes Simplex Virus Treatment Market: Executive Summary
- 2.1 Market Summary
- Chapter 3 Herpes Simplex Virus Treatment Market: Industry Outlook
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.2 Penetration & Growth Prospect Mapping
- 3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
- 3.3.1.1 Growing prevalence of herpes infection
- 3.3.1.2 Development of novel treatment options
- 3.3.1.3 Increasing government funding
- 3.3.1.3 Technological advancements
- 3.3.2 Market Restraint Analysis
- 3.3.2.1 Unavailability of vaccine
- 3.4 Porter’s Five Forces Analysis
- 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
- 3.6 Regulatory Framework
- 3.7 User Perspective Analysis
- Chapter 4 Herpes Simplex Virus Treatment Market: Competitive Landscape
- 4.1 Recent developments & impact analysis, by key market participants
- 4.1.1 Ansoff Matrix
- 4.2 Major deals & strategic alliances analysis
- 4.2.1 Joint Ventures
- 4.2.2 Licensing and Partnerships
- 4.2.3 Technological Collaborations
- 4.3 Company/Competition Categorization
- 4.4 Vendor Landscape
- 4.4.1 List Of Key Distributors and Channel Partners
- 4.4.2 Key Customers
- 4.5 Public Companies
- 4.5.1 Company Market Position Analysis
- 4.6 Private Companies
- 4.6.1 List Of Key Emerging Companies
- 4.6.2 Regional Network Map
- Chapter 5 Herpes Simplex Virus Treatment Market: Treatment Business Analysis
- 5.1 Definition and Scope
- 5.2 Treatment Market Share Analysis, 2021 & 2030
- 5.3 Global Herpes Simplex Virus Treatment Market, By Treatment, 2018 To 2030
- 5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 5.4.1 Herpes Simplex Virus-1 (HSV-1)
- 5.4.1.1 Herpes Simplex Virus-1 (HSV-1) Market 2018 - 2030 (USD Million)
- 5.4.2 Herpes Simplex Virus-2 (HSV-2)
- 5.4.2.1 Herpes Simplex Virus-2 (HSV-2) Market, 2018 - 2030 (USD Million)
- Chapter 6 Herpes Simplex Virus Treatment Market: Drug Business Analysis
- 6.1 Definition and Scope
- 6.2 Drug Market Share Analysis, 2021 & 2030
- 6.3 Global Herpes Simplex Virus Treatment Market, By Drug, 2018 To 2030
- 6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 6.4.1 Acyclovir
- 6.4.1.1 Acyclovir Market 2018 - 2030 (USD Million)
- 6.4.2 Valacyclovir
- 6.4.2.1 Valacyclovir Market, 2018 - 2030 (USD Million)
- 6.4.3 Famciclovir
- 6.4.3.1 Famciclovir Market, 2018 - 2030 (USD Million)
- 6.4.4 Other Drugs
- 6.4.4.1 Other Drugs Market, 2018 - 2030 (USD Million)
- Chapter 7 Herpes Simplex Virus Treatment Market: Vaccine Business Analysis
- 7.1 Definition and Scope
- 7.2 Vaccine Market Share Analysis, 2021 & 2030
- 7.3 Global Herpes Simplex Virus Treatment Market, By Vaccine, 2018 To 2030
- 7.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 7.4.1 Simplirix
- 7.4.1.1 Drug Discovery and Development Market 2018 - 2030 (USD Million)
- 7.4.4 Others
- 7.4.4.1 Others Market, 2018 - 2030 (USD Million)
- Chapter 8 Herpes Simplex Virus Treatment Market: Route of Administration Business Analysis
- 8.1 Definition and Scope
- 8.2 Route of Administration Market Share Analysis, 2021 & 2030
- 8.3 Global Herpes Simplex Virus Treatment Market, By Route of Administration, 2018 To 2030
- 8.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 8.4.1 Oral
- 8.4.1.1 Oral Market 2018 - 2030 (USD Million)
- 8.4.2 Injectable
- 8.4.2.1 Injectable Market, 2018 - 2030 (USD Million)
- 8.4.3 Topical
- 8.4.3.1 Topical Market, 2018 - 2030 (USD Million)
- Chapter 9 Herpes Simplex Virus Treatment Market: End-use Business Analysis
- 9.1 Definition and Scope
- 9.2 End-use Market Share Analysis, 2021 & 2030
- 9.3 Global Herpes Simplex Virus Treatment Market, By End-use, 2018 To 2030
- 9.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 9.4.1 Drug Discovery and Development
- 9.4.1.1 Drug Discovery and Development Market 2018 - 2030 (USD Million)
- 9.4.2 Hospital Pharmacy
- 9.4.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
- 9.4.3 Retail Pharmacy
- 9.4.3.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
- 9.4.4 Online Pharmacy
- 9.4.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)
- Chapter 10 Herpes Simplex Virus Treatment Market: Regional Business Analysis
- 10.1 Definition & Scope
- 10.2 Regional Market Share Analysis, 2021 & 2030
- 10.3 Regional Market Dashboard
- 10.4 Regional Market Snapshot
- 10.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- 10.5.1 North America
- 10.5.2 Europe
- 10.5.3 Asia Pacific
- 10.5.4 Latin America
- 10.5.5 MEA
- 10.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
- 10.7 North America
- 10.7.1 North America Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.7.2 U.S.
- 10.7.2.1 U.S. Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.7.3 Canada
- 10.7.3.1 Canada Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.8 Europe
- 10.8.1 Europe Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.8.2 U.K.
- 10.8.2.1 U.K. Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.8.3 Germany
- 10.8.3.1 Germany Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.8.4 France
- 10.8.4.1 France Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.8.5 Italy
- 10.8.5.1 Italy Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.8.6 Spain
- 10.8.6.1 Spain Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.9 Asia Pacific
- 10.9.1 Asia Pacific Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.9.2 Japan
- 10.9.2.1 Japan Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.9.3 China
- 10.9.3.1 China Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.9.4 India
- 10.9.4.1 India Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.9.5 Australia
- 10.9.5.1 Australia Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.9.6 South Korea
- 10.9.6.1 South Korea Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.10 Latin America
- 10.10.1 Latin America Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.10.2 Brazil
- 10.10.2.1 Brazil Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.10.3 Mexico
- 10.10.3.1 Mexico Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.10.4 Argentina
- 10.10.4.1 Argentina Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.11 MEA
- 10.11.1 MEA Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.11.2 South Africa
- 10.11.2.1 South Africa Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.11.3 Saudi Arabia
- 10.11.3.1 Saudi Arabia Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- 10.11.4 UAE
- 10.11.4.1 UAE Herpes Simplex Virus Treatment Market, 2018 - 2030 (USD Million)
- Chapter 11 Herpes Simplex Virus Treatment Market: Company Profiling
- 11.1 Company Profiles
- 11.1.1 GSK plc
- 11.1.1.1 Company Overview
- 11.1.1.2 Financial Performance
- 11.1.1.3 Product Benchmarking
- 11.1.1.4 Strategic Initiatives
- 11.1.2 Carlsbad Tech
- 11.1.2.1 Company Overview
- 11.1.2.2 Financial Performance
- 11.1.2.3 Product Benchmarking
- 11.1.2.4 Strategic Initiatives
- 11.1.3 Emcure Pharmaceuticals Ltd.
- 11.1.3.1 Company Overview
- 11.1.3.2 Financial Performance
- 11.1.3.3 Product Benchmarking
- 11.1.3.4 Strategic Initiatives
- 11.1.4 Novartis AG
- 11.1.4.1 Company Overview
- 11.1.4.2 Financial Performance
- 11.1.4.3 Product Benchmarking
- 11.1.4.4 Strategic Initiatives
- 11.1.5 Glenmark Pharmaceuticals Inc.
- 11.1.5.1 Company Overview
- 11.1.5.2 Financial Performance
- 11.1.5.3 Product Benchmarking
- 11.1.5.4 Strategic Initiatives
- 11.1.6 Fresenius Kabi AG
- 11.1.6.1 Company Overview
- 11.1.6.2 Financial Performance
- 11.1.6.3 Product Benchmarking
- 11.1.6.4 Strategic Initiatives
- 11.1.7 Apotex Inc.
- 11.1.7.1 Company Overview
- 11.1.7.2 Financial Performance
- 11.1.7.3 Product Benchmarking
- 11.1.7.4 Strategic Initiatives
- 11.1.8 Viatris Inc.
- 11.1.8.1 Company Overview
- 11.1.8.2 Financial Performance
- 11.1.8.3 Product Benchmarking
- 11.1.8.4 Strategic Initiatives
- 11.1.9 Teva Pharmaceuticals Industries Ltd.
- 11.1.9.1Company Overview
- 11.1.9.2 Financial Performance
- 11.1.9.3 Product Benchmarking
- 11.1.9.4 Strategic Initiatives
- 11.1.10 Sanofi
- 11.1.10.1 Company Overview
- 11.1.10.2 Financial Performance
- 11.1.10.3 Product Benchmarking
- 11.1.10.4 Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


